Top Cannabis Investment News, Member Posts, Cannabis Investment Daily Indices and more!

4w ago Cannabis greenmarketreport Views: 277

-

Netflix (NASDAQ: NFLX) has launched four episodes of “How to Change Your Mind” based on the Michael Pollan book of the same name. The four-part docu-series was executive produced by Alex Gibney and directed by Alison Ellwood. The series is based on The New York Times best-selling book and it dives into the science of psychedelics while touching on consciousness, dying, addiction, depression, and transcendence. Each episode targets a different mind-altering substance: LSD, psilocybin, MDMA, and mescaline.

Pollan told Deadline, “The current renaissance in psychedelic research has been the most compelling and hopeful story I’ve covered in thirty years as a journalist. But it’s one thing to describe the powerful effects of these substances in a book, and quite another to evoke that experience, and its incredible potential for healing, on the screen, as the Netflix adaptation of How to Change Your Mind has masterfully done.” Deadline wrote, “With Pollan as a guide, viewers will journey to the frontiers of the new psychedelic renaissance – and look back at the almost-forgotten historical context – to explore the potential of these substances to heal and change minds as well as culture.”

Mainstreaming Psychedelics

-

Pollan also wrote the books This Is Your Mind On Plants, Cooked, Food Rules, In Defense of Food, The Omnivore’s Dilemma and The Botany of Desire. Cooked was adapted as a TV series that is also streaming on Netflix and The Botany of Desire and In Defense of Food premiered on PBS.

It is this literary pedigree that has given Pollan’s book a lot of weight within the psychedelics industry. However, a recent podcast called “Cover Story” from New York Magazine delved into the dark side of the psychedelic industry and one episode featured a conversation with Pollan. Episode 8 titled “Who AmI Fooling” questioned whether Polan’s cheerleading of psychedelics ignored the downsides of these powerful drugs. The podcast hosts fear that the book will make the psychedelic experiences entice many people without any warning of the negatives.

Host Lily Kay Ross said,

Michael listened to the people who called him, he forwarded their letters and put them in touch with key people. They all told us that. And he’s also included more footnotes of caution in his interviews and talks.But it doesn’t compare to the roar of celebration.

 

Netflix Trips

Pollan’s show isn’t the only psychedelics program on Netflix that cuts from the mainstream. Gwyneth Paltrow’s series “The Goop Lab” features an episode on a magic mushroom retreat in Jamaica. It’s lighthearted and cheerful with lots of laughter in a beautiful setting. Then there’s “Have a Good Trip” which features numerous celebrities discussing psychedelics in an original documentary with live-action and animation. So, Pollan’s is just the latest to feature psychedelics on Netflix.

 

Netflix Launches Psychedelic Pollan Series on Green Market Report.


Today's Cannabis Investment Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.